Previous 10 | Next 10 |
BioXcel Therapeutics (BTAI) announces an update to its BXCL501 dementia program.Following the end of Phase 2 meeting with the FDA, the Company plans to finalize study design, dosing, and endpoints for its Phase 3 registrational program, expected to begin in H2. The Company is also providing a...
Review of TRANQUILITY data show ed 30 mcg dose met statistical significance across multiple scales Company initiated supplemental 40 mcg dose cohort to help inform clinical development strategy across the full range of dementia care settings End of Phase 2 meeting ...
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today...
BioXcel Therapeutics (BTAI) announces the initiation of a Phase 2 PLACIDITY trial of BXCL501, the company’s investigational orally dissolving thin film formulation of dexmedetomidine ((Dex)), for the treatment of delirium related agitation.The PLACIDITY trial is a multicente...
NEW HAVEN, Conn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience...
NEW HAVEN, Conn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience...
Gainers: vTv Therapeutics (NASDAQ: VTVT ) +169% . Cool Holdings (NASDAQ: AWSM ) +58% . Estre Ambiental (NASDAQ: ESTR ) +34% . PLx Pharma (NASDAQ: PLXP ) +31% . OPKO Health (NYSEMKT: OPK ) +30% . Quantum Corporation (NYSE: QTM ) +28% . Mersana Therapeutics (NASDAQ: MRSN ) +28% ...
Gainers: Energous Corporation (NASDAQ: WATT ) +95% . BioXcel Therapeutics (NASDAQ: BTAI ) +81% . CounterPath (NASDAQ: CPAH ) +25% . Novus Therapeutics (NASDAQ: NVUS ) +21% . LiveXLive Media (NASDAQ: LIVX ) +19% . Netshoes (NYSE: NETS ) +17% . Avadel Pharmaceuticals (NASDAQ: AVDL ) ...
CORAL GABLES, FL / ACCESSWIRE / December 27, 2018 / With the new year less than one week away, the healthcare industry is effervescent with excitement as companies work towards designing new methods and technologies to dramatically improve care options available to consumers. As medical ...
BioXcel's (NASDAQ: BTAI ) investigational drug BXCL501 - a proprietary sublingual film of dexmedetomidine, for the treatment of acute agitation - has been granted Fast Track Designation by the FDA. More news on: BioXcel Therapeutics, Healthcare stocks news, Stocks on the move, Rea...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2024 financ...
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...